The DESIRE study has been completed.
The DESIRE study has been completed. This global study, also referred to as MTN-035, evaluated three placebo methods (douche, insert and suppository) for the delivery of a rectal microbicide at sites in Malawi, Peru, South Africa, Thailand and the U.S. An incredible effort by DESIRE study leadership, teams, sites and participants enabled the safe and timely completion of the study in the midst of the COVID-19 pandemic. The study enrolled 210 transgender men and women and cisgender men who have sex with men. We excitedly await results in 2021.